These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa. Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700 [TBL] [Abstract][Full Text] [Related]
7. New strategies in dopaminergic therapy of Parkinson's disease: the use of a controlled-release formulation. London, England, April 28 and 29, 1989. Proceedings. Neurology; 1989 Nov; 39(11 Suppl 2):1-106. PubMed ID: 2586761 [No Abstract] [Full Text] [Related]
8. Medical treatment of Parkinson's disease. Ahlskog JE Compr Ther; 1989 Mar; 15(3):53-9. PubMed ID: 2650977 [No Abstract] [Full Text] [Related]
9. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment. Zimmerman TR; Sage JI; Lang AE; Mark MH Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678 [TBL] [Abstract][Full Text] [Related]
10. The effects of combining carbidopa with levodopa for Parkinson's disease. Martin WE; Tolosa ES; Loewenson RB; Lee MC; Resch JA; Baker AB Geriatrics; 1975 Dec; 30(12):39-44. PubMed ID: 1104406 [No Abstract] [Full Text] [Related]
11. Carbidopa/levodopa therapy of coexistent drug-induced parkinsonism and tardive dyskinesia. Shoulson I Adv Neurol; 1983; 37():259-66. PubMed ID: 6134445 [No Abstract] [Full Text] [Related]
12. [A year of treatment with carbidopa and levodopa in Parkinsonian patients]. Martínez-Lage JM; Marti-Massó JF; Delgado G; Carreray N; Del Amo F Rev Clin Esp; 1974 Sep; 134(6):535-42. PubMed ID: 4450036 [No Abstract] [Full Text] [Related]
13. Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease. Rondot P; Ziegler M; Aymard N; Teinturier A Neurology; 1989 Nov; 39(11 Suppl 2):74-7; discussion 95. PubMed ID: 2586765 [TBL] [Abstract][Full Text] [Related]
14. Treating motor fluctuations with controlled-release levodopa preparations. Koller WC; Pahwa R Neurology; 1994 Jul; 44(7 Suppl 6):S23-8. PubMed ID: 8047257 [TBL] [Abstract][Full Text] [Related]
16. The use of Sinemet CR in the management of mild to moderate Parkinson's disease. Rodnitzky RL Neurology; 1992 Jan; 42(1 Suppl 1):44-50; discussion 57-60. PubMed ID: 1549201 [TBL] [Abstract][Full Text] [Related]
17. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease. Hutton JT; Morris JL; Bush DF; Smith ME; Liss CL; Reines S Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652 [TBL] [Abstract][Full Text] [Related]
18. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect. Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340 [TBL] [Abstract][Full Text] [Related]
19. New and emerging strategies for improving levodopa treatment. Tolosa ES; Valldeoriola F; Martí MJ Neurology; 1994 Jul; 44(7 Suppl 6):S35-44. PubMed ID: 8047259 [TBL] [Abstract][Full Text] [Related]